Aligos Therapeutics, Inc.
ALGS- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001799448
No open-market purchases or sales by Aligos Therapeutics, Inc. insiders were filed in the last 90 days; 31 institutions reported holding it in 13F filings for Q2 2026, worth $13.2M in total; HHLR Advisors (Hillhouse) is the only superinvestor holding it.
Q1 2024 vs. Q4 2023
How the institutions holding Aligos Therapeutics, Inc. changed between Q4 2023 and Q1 2024.
All holders in Q1 2024All holders in Q4 2023
| Measure | Q4 2023 | Q1 2024 | Change |
|---|---|---|---|
| Holders | 40 | 49 | +9 |
| Shares | 45.4M | 46.2M | +863.8K (+1.9%) |
| Value | $30.1M | $45.3M | +$15.2M (+50.4%) |
New holders (11)
Institutions that held Aligos Therapeutics, Inc. at the end of Q1 2024 but not at the end of Q4 2023.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Adage Capital Partners GP, L.L.C. | 2,464,505 | $2.42M | 0.00% |
| UBS Oconnor LLC | 500,000 | $490.0K | 0.01% |
| Citadel Advisors LLC | 285,679 | $280.0K | 0.00% |
| Atom Investors LP | 34,173 | $33.5K | 0.00% |
| Procyon Private Wealth Partners, LLC | 20,000 | $19.6K | 0.00% |
| ZWJ Investment Counsel Inc | 14,500 | $14.2K | 0.00% |
| Vontobel Holding Ltd. | 12,500 | $12.3K | 0.00% |
| UBS Group AG | 10,825 | $10.6K | 0.00% |
| Financial Advocates Investment Management | 10,000 | $9.80K | 0.00% |
| Total Clarity Wealth Management, Inc. | 10,000 | $9.80K | 0.00% |
| Simplex Trading, LLC | 1,104 | $1.00K | 0.00% |
Sold out (2)
Institutions that held Aligos Therapeutics, Inc. at the end of Q4 2023 and filed for Q1 2024 without it.
| Institution | Shares, Q4 2023 | Value, Q4 2023 |
|---|---|---|
| Alyeska Investment Group, L.P. | 2,882,216 | $1.91M |
| Two Sigma Securities, LLC | 14,739 | $9.79K |